Cytological Biomarkers

Cytology have been act as a main tools utilised in the diagnosis of cancer. These techniques have evolved from an era of diagnosis based on haematoxylin and eosin (H&E) stained slides  to the current regular evaluation of tumours by immunocytochemistry (IHC) to confirm tumour histogenesis and subtype. In breast cancer, this means the routine IHC evaluation of hormone receptors (oestrogen and progesterone receptors) as well as evaluation of HER2 expression  and Ki67 (a marker of tumour proliferation). These factors strongly influence prognosis and the selection of anti-cancer treatments.

 

  • cytological carcinoma
  • Cytopathology marker

Related Conference of Cytological Biomarkers

July 28-29, 2025

45th Euro Congress on Cancer Science & Therapy

Paris, France
October 20-21, 2025

21st International Conference on Cancer Research

Barcelona, Spain
October 22-23, 2025

35th Experts Meet On Cancer Research & Therapy

Paris, France
October 24-25, 2025

25th World Congress on Cancer and Diagnostics

Zurich, Switzerland
November 20-21, 2025

26th World Congress on Cancer Summit

Amsterdam, Netherlands
November 24-25, 2025

43rd World Cancer Conference

Barcelona, Spain
December 08-09, 2025

13th Euro Breast Cancer and Therapeutics

Aix-en-Provence, France
February 05-06, 2026

11th World Conference on Breast and Cervical Cancer

Paris, France
February 12-13, 2026

4th World Congress on Oral Cancer

Singapore City, Singapore
February 19-20, 2026

7th Cancer Diagnostics & Treatment Conference

Miami, USA
February 19-20, 2026

8th International Conference on Women Oncology

Miami, USA
March 23-24, 2026

16th World Congress on Breast Cancer Research & Therapies

Aix-en-Provence, France

Cytological Biomarkers Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in